Table 3 Association of markers of PI3K/AKT/mTOR pathway activity with clinical outcome

From: Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

Basal biomarker

n (%)

DCR at 12 weeks (%)

P value

Median PFS (95% CI), months

P value

Median OS (95% CI), months

P value

p-S6 Ser 235/236

  Low

14 (67)

6 (43)

0.659

3.0 (1.4–12.7)

0.792

8.5 (2.5–16.6)

0.281

  High

7 (33)

4 (57)

6.0 (1.1–NR)

9.5 (1.1–20.5)

p-S6 Ser 240/244

  Low

13 (62)

7 (54)

0.659

5.8 (1.4–12.7)

0.471

14.4 (2.47–18.6)

0.378

  High

8 (38)

3 (37)

3.0 (1.1–NR)

6.6 (1.09–16.6)

p-mTOR

  Low

15 (68)

6 (40)

0.685

5.5 (1.4–12.7)

0.295

9.5 (5.5–16.6)

0.851

  High

7 (32)

3 (43)

2.5 (1.1–8.4)

6.7 (1.1–17.1)

p-AKT Ser 473

  Low

14 (67)

7 (50)

1

5.5 (1.4–11.2)

0.409

8.1 (1.81–16.6)

0.853

  High

7 (33)

3 (43)

6.0 (1.41–NR)

9.5 (4.38–19.6)

p-4EBP1

  Low

13 (62)

8 (61)

0.183

6.0 (1.4–16.8)

0.143

14.4 (2.5–19.9)

0.052

  High

8 (38)

2 (25)

2.6 (1.09–NR)

6.6 (1.09–16.5)

PTEN

  Low

5 (24)

3 (60)

0.635

7.1 (2.8–NR)

0.844

16.6 (5.6–NR)

0.621

  High

16 (76)

7 (44)

5.5 (1.4–16.8)

7.2 (2.5–17.1)

  1. CI confidence interval, NR not reached
Back to article page